2.Rodger, AJ, et al. (2013) Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27, 973–979.
3.Antinori, A, et al. (2017) Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiologica 40, 86–98.
4.Anglemyer, A, et al. (2013) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples (review). Cochrane Database Syst Rev. Apr 30;4:CD009153. doi:10.1002/14651858.CD009153.
5.Chan, AK, et al. (2016) Same day HIV diagnosis and antiretroviral therapy initiation affects retention in Option B+ prevention of mother-to-child transmission services at antenatal care in Zomba District, Malawi. Journal of the International AIDS Society 19(1), 20672.
6.Gardner, EM, et al. (2011) The spectrum of engagement in HIV care and its relevance to test-and treat strategies for prevention of HIV infection. Clinical Infectious Diseases 52(6), 793–800.
7.Centers for Disease Control and Prevention (CDC) (2011) Vital signs: HIV prevention through care and treatment – United States. MMWR. Morbidity and Mortality Weekly Report 60, 1618–1623.
8.Mammone, A, et al. (2016) How many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance data. AIDS. 2016 Apr 24;30(7), 1131–1136.
9.Raimondo, M, et al. ICAR 2016 second national census among people diagnosed with HIV and in care in Italy in 2014. Abs 82.
11.Mammone, A, et al. (2016) How many people are living with undiagnosed HIV infection? An estimate for Italy, based on surveillance data. AIDS 30, 1131–1136.
12.Zona, S, et al. ICAR 2015 characteristics of HIV infected patients not retained in care in three cohorts of Italy. Abs 140.
13.Mugavero, MJ, et al. (2013) The state of engagement in HIV care in the United States: from cascade to continuum to control. Clinical Infectious Diseases 57, 1164–1171.
14.Nachega, JB, et al. (2014). Addressing the Achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clinical Infectious Diseases 59(Suppl 1): S21–S27.
15.Mugavero, MJ (2008) Improving engagement in HIV care: what can we do? Topics in HIV Medicine 16, 156–161.
16.Mugavero, MJ, et al. (2009) Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clinical Infectious Diseases 48, 248–256.
17.Ulett, KB, et al. (2009) The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care and STDs 23, 41–49.
18.Fraccaro, P, et al. (2013) The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Medicine 2 0 2(2), e5.
19.Hernando, V, et al. (2015) HIV infection in migrant populations in the European Union and European Economic Area in 2007–2012; an epidemic on the move. Journal of Acquired Immune Deficiency Syndromes 70, 204–211.
20.Saracino, A, et al. (2016) Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection 22, 288el–288e8.
21.Lima, V, et al. (2009) Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Social Science & Medicine 68(6), 1044–1049.
22.Oh, DL, et al. (2009) Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among white, Hispanic and black men in the MACS Cohort. Journal of Acquired Immune Deficiency Syndromes 52, 290–293.
23.Di Biagio, A, et al. (2016) Discontinuation of initial antiretroviral therapy in clinical practice: moving towards individualized therapy. Journal of Acquired Immune Deficiency Syndromes 71(3), 263–271.
24.Thierfelder, C, et al. (2012) Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV Medicine 13, 118–126.
25.Antinori, A, et al. (2011) Late presentation of HIV infection: a consensus definition. HIV Medicine 12, 61–64.
26.Mocroft, A, et al. (1998) The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Archives of Internal Medicine 158(5), 491–497.
27.Phillips, AN, et al. (2003) When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 17, 1863–1869.
28.INSIGHT START Study Group (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. New England Journal of Medicine 373(9), 795–807.
29.Temprano ANRS 12136 Study Group (2015) A trial of early antiretrovirals and isoniazid preventive therapy in Africa. New England Journal of Medicine 373(9), 808–822.
30.Cohen, M, Chen, Y and McCauley, M (2016) Antiretroviral therapy for the prevention of HIV-1 transmission. New England Journal of Medicine 375, 830–839.
31.Wood, E, et al. (2005) Why are baseline HIV RNA levels 100,000 copies/ml or greater associated with mortality after the initiation of antiretroviral therapy? Journal of Acquired Immune Deficiency Syndromes 38, 289–295.
32.Di Biagio, A, et al. (2014) The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Journal of Medical Virology 86, 1648–1655.
34.Piot, P, et al. (2015) A UNAIDS-lancet commission on defeating AIDS – advancing global health. Lancet 386, 171–218.
35.Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord (2017) Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. AIDS 31(6), 835–846.